SoMOSA:Study of Mechamisms of Action of Omalizumab in Severe Asthma
Research type
Research Study
Full title
SoMOSA: Study of Mechanisms of Action of Omalizumab in Severe Asthma.
IRAS ID
183559
Contact name
Ratko Djukanovic
Contact email
Sponsor organisation
University Hospital NHS Foundation Trust
Duration of Study in the UK
3 years, 11 months, 30 days
Research summary
In this study; we are recruiting patients who will be receiving treatment with the already licensed asthma medication - Xolair (omalizumab) routinely as part of their normal care. During their clinic visits we will be collecting data and research samples to identify biomarkers that will show which participants respond well to Xolair (omalizumab) and which participants do not. Xolair is currently licenced in the UK to treat patients with severe asthma but it is clear that not everyone with severe asthma will benefit from treatment. This data collected from the study of samples and the other tests and questionnaires may provide further information for researchers to understand the reasons why.
REC name
Wales REC 5
REC reference
15/WA/0302
Date of REC Opinion
24 Aug 2015
REC opinion
Favourable Opinion